Evaluating the therapeutic potential of different sources of mesenchymal stem cells in acute respiratory distress syndrome
In different preclinical studies, different sources of MSCs derived from adipose tissue, bone marrow, placenta, umbilical cord have shown effectiveness in treating ARDS. However, their clinical translation has not been effective as demonstrated by variable outcomes from clinical trials. One reason for this could be the MSC source chosen for clinical translation as there is lack of study comparing the different sources of MSCs. In previous work, we performed a “head-to-head” comparison between different sources of MSCs and showed that each source had a unique genomic and proteomic “signature”. Hence, in this current study, we investigated the choice of MSC source best suited for therapy in an LPS-induced mouse model of ARDS.  We compare the 3 most commonly used MSC sources: bone marrow derived-MSCs (BM-MSCs), adipose tissue derived-MSCs (AD-MSCs) and umbilical cord derived-MSCs (UC-MSCs) therapy in LPS-induced ARDS model where we did bulk RNA sequencing of the lungs to validate the efficacy of therapy in terms of different changes in gene label and different pathways involved. Overall design: ARDS was induced via an intra-tracheal injection of lipopolysaccharide (LPS)at the dose of 5mg/kg in phosphate buffered saline (PBS). After 4h following LPS injection, mice were randomized to receive a single intravenous injection of 1x10^6 MSCs (of a single source) or PBS. After 48 hours, whole lung tissue was collected and homogenized in trizol (Thermofisher Scientific, USA). RNA extraction was then done using RNA mini kit (Qiagen, Germany) according to the manufacturer's guidelines with the quality of RNA evaluated using an Agilent bioanlyzer 2100 system. Samples with RNA integrity number (RIN) = 6.8 were considered for library preparation.